# Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin

> **NCT00501020** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 750 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rosiglitazone

## Key facts

- **NCT ID:** NCT00501020
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06-05
- **Primary completion:** 2003-02-13
- **Final completion:** 2003-02-13
- **Target enrollment:** 750 (—)
- **Last updated:** 2017-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00501020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00501020, "Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00501020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*